Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    137
    ...
ATC Name B/G Ingredients Dosage Form Price
B05XA01 CHLORURE DE POTASSIUM PROAMP G Potassium chloride - 0.0746g/ml 0.0746g/ml Injectable concentrated solution 1,444,631 L.L
C09CA07 TOLURA G Telmisartan - 40mg 40mg Tablet 532,162 L.L
C10AA07 APO-ROSUVASTATIN G Rosuvastatin (calcium) - 40mg 40mg Tablet 599,354 L.L
G04BE09 VARI G Vardenafil (HCl) - 20mg 20mg Tablet 1,331,044 L.L
J01DB04 CEFAZOLINE LDP-LABORATORIOS TORLAN G Cefazolin (sodium) - 1g 1g Injectable powder for solution 1,631,425 L.L
J01MA02 CIPROX G Ciprofloxacine (lactate) - 200mg/100ml 0.2%w/v Injectable solution 520,067 L.L
L01EB02 TARESSA 100 G Erlotinib (HCl) - 100mg 100mg Tablet, film coated 82,247,256 L.L
L02BG04 APO-LETROZOLE G Letrozole - 2.5mg 2.5mg Tablet 1,962,010 L.L
M01AB05 DICLOGESIC 12.5 CHILDREN G Diclofenac sodium - 12.5mg 12.5mg Suppository 83,318 L.L
N07XX02 TEGLUTIK G Riluzole - 5mg/ml 5mg/ml Suspension 9,574,189 L.L
R05CB06 MUCOVIC FORTE G Ambroxol HCl - 30mg/5ml 30mg/5ml Solution, sugar free 293,086 L.L
S02AA15 CETRAXAL OTICO G Ciprofloxacine (HCl) - 3mg/ml 3mg/ml Drops 821,088 L.L
A10BA02 METFORMINE ARROW LAB G Metformin - 500mg 500mg Tablet, film coated 193,513 L.L
A11DB MED-PRINCO-B FORT G Vitamin B12 - 200mcg, Vitamin B6 - 200mg, Vitamin B1 - 100mg Tablet, coated 386,515 L.L
B03BB01 MED-FOLIC ACID G Folic acid - 5mg 5mg Tablet, scored 355,798 L.L
B05XA01 CHLORURE DE POTASSIUM RENAUDIN G Potassium chloride - 7.46g/100ml 7.46% Injectable solution 385,683 L.L
C10AA07 ROSUCOR G Rosuvastatin (calcium) - 40mg 40mg Tablet, film coated 487,623 L.L
G04BE09 VERDA G Vardenafil (HCl) - 10mg 10mg Tablet, orally disintegrating 1,023,880 L.L
J01DB04 HIKMA CEFAZOLIN G Cefazolin (sodium) - 1g 1,000mg Injectable solution 215,015 L.L
J01MA02 ESTECINA 200MG G Ciprofloxacine (lactate) - 200mg/100ml 200mg/100ml Injectable solution 32,190,251 L.L
L01EB02 APO-ERLOTINIB G Erlotinib (HCl) - 150mg 150mg Tablet 91,523,229 L.L
L02BG04 FEMAPLEX G Letrozole - 2.5mg 2.5mg Tablet, film coated 1,583,046 L.L
N01AX03 KETAMINE PANPHARMA G Ketamine HCl - 250mg/5ml 250mg/5ml Injectable solution 1,534,668 L.L
R05CB06 MUCOVIC FORTE G Ambroxol HCl - 30mg/5ml 30mg/5ml Solution, sugar free 440,268 L.L
A10BA02 METFORMINE ARROW LAB G Metformin - 500mg 500mg Tablet, film coated 560,382 L.L
A11DB NEUROMED G Vitamin B12 - 200mcg, Vitamin B6 - 200mg, Vitamin B1 - 100mg Tablet, coated 257,250 L.L
B05XA01 POTASSIUM CHLORIDE G Potassium chloride - 7.46g/100ml 7.46g/100ml Injectable solution 2,822,386 L.L
C09CA07 ARBIVASTEL G Telmisartan - 80mg 80mg Tablet 667,890 L.L
C10AA07 ROSUPHAR G Rosuvastatin (calcium) - 40mg 40mg Tablet, film coated 487,623 L.L
G04BE09 LEVIDOR G Vardenafil (HCl) - 5mg 5mg Tablet 876,185 L.L
    ...
    137
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026